Learn Why The Bull Case For Vera Therapeutics Stock Could Change Following Phase III Trial Success

Vera Therapeutics (VERA) fell 7.23% after Leerink initiated coverage with a Market Perform rating, citing overly optimistic expectations for Trutakna's market share and peak sales. Leerink set a $34 price target, suggesting limited upside. Vera has no commercial revenue, increasing risks if Trutakna's demand is slower than expected.

Alignment Healthcare (ALHC) shares dropped 24.2% to $6.60 in pre-market trading after its largest California contract was downgraded to 3.5 stars, making it ineligible for bonus payments. Several other stocks also fell, including Entera Bio (ENTX), AT&T (T), Verizon (VZ), and RenX Enterprises (RENX).

Vera Therapeutics (VERA) reported positive final trial results for TRUTAKNA, meeting all endpoints in the ORIGIN 3 trial for IgA nephropathy. The data showed strong kidney function preservation and safety comparable to placebo. The company plans to use the data for a supplemental BLA filing in late 2026, which could expand TRUTAKNA's label. Vera Therapeutics currently has no meaningful revenue and a net loss of $401.9M, with a share price down 33% year-to-date.

Vera Therapeutics (VERA) shares rose after the company reported final Phase 3 data showing its kidney drug TRUTAKNA reduced disease progression risk by 76% and stabilized kidney function. The results support a planned FDA filing for late 2026, with strong early launch metrics and heavy options trading. However, the company has no product revenue, rising losses, and cash burn, requiring successful sales and potential capital raising to sustain operations.

Vera Therapeutics reported positive two-year Phase 3 trial results for Trutakna, showing a 76% reduction in kidney-disease progression risk vs. placebo. The drug met all efficacy endpoints and demonstrated improved kidney function. Vera plans to submit for full FDA approval in Q4 2026, aiming for a 2027 decision. The company has seen early commercial adoption with 350+ patient starts in 10 weeks.

Vera Therapeutics (VERA) reported that TRUTAKNA stabilized kidney function in IgA nephropathy patients over two years in the ORIGIN 3 trial. The company plans to submit a supplemental Biologics License Application in Q4 2026. Shares rose 12% following the update. The trial met all endpoints, showing a 5.0mL/min/1.73m2 benefit in kidney filtration rates compared to placebo.